{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:23:34Z","timestamp":1794939814172,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014688","name":"Region Uppsala","doi-asserted-by":"crossref","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/501100014688","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007949","name":"the Swedish Rheumatism Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"crossref"}]},{"name":"King Gustaf V's 80-years Foundation"},{"name":"the Swedish Society of Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hydroxychloroquine (HCQ) is the standard of care in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other inflammatory rheumatic diseases and potentially for the treatment in COVID-19 patients. Determination of HCQ for therapeutic drug monitoring (TDM) can be performed in whole blood (WB), serum, and plasma. Direct comparisons of WB, serum, and plasma levels of HCQ in patients with SLE have not previously been reported. We describe a method for the determination of HCQ in human blood using liquid chromatography-high-resolution mass spectrometry (LC-HRMS) and compare the suitability of the three sample matrices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A method for the determination of HCQ in human blood using LC-HRMS was developed, validated, and applied for the determination of HCQ levels in WB, serum, and plasma from 26 SLE patients. The reproducibility of the method, in the three matrices, was evaluated using quality control samples and repeated preparations and measurements of patient samples. The performance of the developed method for HCQ measurement in serum was further evaluated by comparison with two previously reported extraction methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The performance of the presented method demonstrated high accuracy and precision. A large range of HCQ concentrations was observed for the SLE patients in all three matrices (WB, serum, and plasma). The mean levels in WB were approximately two-fold the levels in serum and plasma (813\u2009ng\/mL compared to 436\u2009ng\/mL and 362\u2009ng\/mL, respectively). Spiked quality controls showed high reproducibility for all matrices (coefficient of variation, CV, approx. 5%), whereas in patient samples, equally high-precision was only found using WB as the matrix (CV 3%). The CV for serum and plasma was 14% and 39%, respectively. Two alternative methods applied to serum samples did not demonstrate improved precision.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A LC-HRMS method for the measurement of HCQ in human blood was developed and validated. Whole blood was found to be the superior sample matrix in terms of sample reproducibility. Thus, whole blood samples should be used for HCQ analysis when patients are monitored for HCQ treatment effects. The assay is in clinical use to monitor levels of HCQ in patients.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13075-020-02211-1","type":"journal-article","created":{"date-parts":[[2020,5,31]],"date-time":"2020-05-31T23:03:49Z","timestamp":1590966229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS\u2014evaluation of whole blood, plasma, and serum as sample matrices"],"prefix":"10.1186","volume":"22","author":[{"given":"Henrik","family":"Carlsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hjorton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Abujrais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"R\u00f6nnblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f6rn","family":"\u00c5kerfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0680-1410","authenticated-orcid":false,"given":"Kim","family":"Kultima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"issue":"4","key":"2211_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","volume":"39","author":"Guillermo J. Pons-Estel","year":"2010","unstructured":"Pons-Estel GJ, Alarc\u00f3n GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheumatism. 2010:257\u201368. https:\/\/doi.org\/10.1016\/j.semarthrit.2008.10.007.","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"1","key":"2211_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/joim.12529","volume":"281","author":"A. A. Bengtsson","year":"2016","unstructured":"Bengtsson AA, R\u00f6nnblom L. Systemic lupus erythematosus: still a challenge for physicians. J Intern Med. 2017:52\u201364. https:\/\/doi.org\/10.1111\/joim.12529.","journal-title":"Journal of Internal Medicine"},{"key":"2211_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3949\/ccjm.85a.17034","volume":"85","author":"EA Shippey","year":"2018","unstructured":"Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: an old drug with new relevance. Cleve Clin J Med. 2018;85:459\u201367.","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"2211_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"Josef S Smolen","year":"2013","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheumatic Dise. 2014:492\u2013509. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204573.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"2211_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155\u201366.","journal-title":"Nat Rev Rheumatol"},{"key":"2211_CR6","doi-asserted-by":"publisher","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"issue":"12","key":"2211_CR7","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1002\/art.34672","volume":"64","author":"Michelle Petri","year":"2012","unstructured":"Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheumatism. 2012:4021\u20138. https:\/\/doi.org\/10.1002\/art.34672.","journal-title":"Arthritis & Rheumatism"},{"key":"2211_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2211_CR9","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1002\/art.22156","volume":"54","author":"Nathalie Costedoat-Chalumeau","year":"2006","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot J-S, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheumatism. 2006:3284\u201390. https:\/\/doi.org\/10.1002\/art.22156.","journal-title":"Arthritis & Rheumatism"},{"key":"2211_CR10","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3899\/jrheum.150379","volume":"42","author":"L Durcan","year":"2015","unstructured":"Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42:2092\u20137.","journal-title":"J Rheumatol"},{"issue":"1","key":"2211_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3899\/jrheum.180158","volume":"46","author":"Stephen J. Balevic","year":"2018","unstructured":"Balevic SJ, Cohen-Wolkowiez M, Eudy AM, Green TP, Schanberg LE, Clowse MEB. Hydroxychloroquine levels throughout pregnancies complicated by rheumatic disease: implications for maternal and neonatal outcomes. J Rheumatol. 2019:57\u201363. https:\/\/doi.org\/10.3899\/jrheum.180158.","journal-title":"The Journal of Rheumatology"},{"issue":"8","key":"2211_CR12","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1002\/art.39194","volume":"67","author":"M. Jallouli","year":"2015","unstructured":"Jallouli M, Galicier L, Zahr N, Auma\u00eetre O, Franc\u00e8s C, Le Guern V, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015:2176\u201384. https:\/\/doi.org\/10.1002\/art.39194.","journal-title":"Arthritis & Rheumatology"},{"key":"2211_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/ard.2006.067835","volume":"66","author":"N Costedoat-Chalumeau","year":"2007","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot J-S, Aymard G, Leroux G, Marra D, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821\u20134.","journal-title":"Ann Rheum Dis"},{"key":"2211_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.39402","volume":"68","author":"JY Lee","year":"2016","unstructured":"Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2016;68:184\u201390.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"2211_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"Ronald B. Melles","year":"2014","unstructured":"Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453\u201360.","journal-title":"JAMA Ophthalmology"},{"issue":"3","key":"2211_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/art.41121","volume":"72","author":"Michelle Petri","year":"2020","unstructured":"Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol. 2019. https:\/\/doi.org\/10.1002\/art.41121.","journal-title":"Arthritis & Rheumatology"},{"issue":"6","key":"2211_CR17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"Michael F. Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016:1386\u201394. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.058.","journal-title":"Ophthalmology"},{"issue":"3","key":"2211_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/BOR.0000000000000500","volume":"30","author":"Nada Abdulaziz","year":"2018","unstructured":"Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine. Curr Opin Rheumatol. 2018:249\u201355. https:\/\/doi.org\/10.1097\/bor.0000000000000500.","journal-title":"Current Opinion in Rheumatology"},{"issue":"11","key":"2211_CR19","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","volume":"72","author":"Nathalie Costedoat-Chalumeau","year":"2012","unstructured":"Costedoat-Chalumeau N, Galicier L, Auma\u00eetre O, Franc\u00e8s C, Le Guern V, Liot\u00e9 F, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis. 2013:1786\u201392. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202322.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"2211_CR20","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/acr.22837","volume":"68","author":"CC Mok","year":"2016","unstructured":"Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res. 2016;68:1295\u2013302.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"2211_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40262-018-0712-z","volume":"58","author":"Stephen J. Balevic","year":"2018","unstructured":"Balevic SJ, Green TP, Clowse MEB, Eudy AM, Schanberg LE, Cohen-Wolkowiez M. Pharmacokinetics of hydroxychloroquine in pregnancies with rheumatic diseases. Clin Pharmacokinetics. 2019:525\u201333. https:\/\/doi.org\/10.1007\/s40262-018-0712-z.","journal-title":"Clinical Pharmacokinetics"},{"key":"2211_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2125.1988.tb05281.x","volume":"26","author":"SE Tett","year":"1988","unstructured":"Tett SE, Cutler DJ, Day RO, Brown KF. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1988;26:303\u201313.","journal-title":"Br J Clin Pharmacol"},{"key":"2211_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cca.2013.02.018","volume":"421","author":"AK F\u00fcz\u00e9ry","year":"2013","unstructured":"F\u00fcz\u00e9ry AK, Breaud AR, Emezienna N, Schools S, Clarke WA. A rapid and reliable method for the quantitation of hydroxychloroquine in serum using turbulent flow liquid chromatography-tandem mass spectrometry. Clin Chim Acta. 2013;421:79\u201384.","journal-title":"Clin Chim Acta"},{"key":"2211_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jpba.2014.07.009","volume":"100","author":"Marion Soichot","year":"2014","unstructured":"Soichot M, M\u00e9garbane B, Houz\u00e9 P, Chevillard L, Fonsart J, Baud FJ, et al. Development, validation and clinical application of a LC-MS\/MS method for the simultaneous quantification of hydroxychloroquine and its active metabolites in human whole blood. J Pharm Biomed Anal. 2014:131\u20137. https:\/\/doi.org\/10.1016\/j.jpba.2014.07.009.","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2211_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40744-015-0012-0","volume":"2","author":"H-W Fan","year":"2015","unstructured":"Fan H-W, Ma Z-X, Chen J, Yang X-Y, Cheng J-L, Li Y-B. Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC-MS\/MS. Rheumatol Ther. 2015;2:183\u201395.","journal-title":"Rheumatol Ther"},{"key":"2211_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jpba.2011.11.034","volume":"61","author":"L-Z Wang","year":"2012","unstructured":"Wang L-Z, Ong RY-L, Chin T-M, Thuya W-L, Wan S-C, Wong AL-A, et al. Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012;61:86\u201392.","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"2211_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"Eng M. Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatism. 1982:1271\u20137. https:\/\/doi.org\/10.1002\/art.1780251101.","journal-title":"Arthritis & Rheumatism"},{"key":"2211_CR28","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai A-M, Alarc\u00f3n GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677\u201386.","journal-title":"Arthritis Rheum"},{"key":"2211_CR29","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288\u201391.","journal-title":"J Rheumatol"},{"key":"2211_CR30","doi-asserted-by":"publisher","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015. https:\/\/doi.org\/10.18637\/jss.v067.i01.","DOI":"10.18637\/jss.v067.i01"},{"key":"2211_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/BF00315548","volume":"44","author":"AJ McLachlan","year":"1993","unstructured":"McLachlan AJ, Cutler DJ, Tett SE. Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. Eur J Clin Pharmacol. 1993;44:481\u20134.","journal-title":"Eur J Clin Pharmacol"},{"key":"2211_CR32","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/art.10307","volume":"46","author":"T Munster","year":"2002","unstructured":"Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1460\u20139.","journal-title":"Arthritis Rheum"},{"key":"2211_CR33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0889-857X(21)00233-7","volume":"20","author":"DJ Wallace","year":"1994","unstructured":"Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin N Am. 1994;20:243\u201363.","journal-title":"Rheum Dis Clin N Am"},{"key":"2211_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","volume":"27","author":"SE Tett","year":"1989","unstructured":"Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27:771\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2211_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.semarthrit.2018.01.002","volume":"48","author":"Candace H. Feldman","year":"2018","unstructured":"Feldman CH, Collins J, Zhang Z, Subramanian SV, Solomon DH, Kawachi I, et al. Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthritis Rheum. 2018;48:205\u201313.","journal-title":"Seminars in Arthritis and Rheumatism"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02211-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T21:40:48Z","timestamp":1666734048000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02211-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2211"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02211-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"29 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent, and the study was approved by the Regional Ethical Board of Uppsala (Dnr: 2019-02031).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}